HH Have COVID-19 Vaccines Shifted The Pharma Pricing Debate?

And people are driving two hours to get them in some cases.

However, shots are going into arms. COVID-19 death numbers are coming down, and it feels like life could return to relative normal one of these days.

During the election, there was a lot of talk about forcing drug companies to lower prices. You don’t hear much about that now.

At some point, when COVID-19 is a bad memory, the issue will likely rear its head again. But I suspect Big Pharma and biotech earned themselves a grace period for a little while.

And despite the industry’s cheesy commercials with couples in outdoor bathtubs and women looking longingly at their newly virile partners, it has proved just how valuable its work is.

Big Pharma and biotech are more or less recession-proof because a patient is generally not going to stop taking life-saving medicine just because the economy or the market is bad.

But now that they may have the government off their back for a little while, drug companies may not have to worry about lowering prices, shrinking margins, and smaller profits.

That could lead to strong earnings for plenty of companies that have nothing to do with COVID-19 but will benefit from the goodwill that the vaccine-makers have earned.

Next Monday, I’m going to talk about my favorite way to invest in biotech and a very personal experience regarding this important factor.

1 2
View single page >> |

Disclaimer: Nothing published by Wealthy Retirement should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.